Free Trial

Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics logo
$51.59 -0.40 (-0.77%)
(As of 11:51 AM ET)

Janux Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
9

Based on 10 Wall Street analysts who have issued ratings for Janux Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for JANX.

Consensus Price Target

$66.44
28.79% Upside
According to the 10 analysts' twelve-month price targets for Janux Therapeutics, the average price target is $66.44. The highest price target for JANX is $100.00, while the lowest price target for JANX is $42.00. The average price target represents a forecasted upside of 28.79% from the current price of $51.59.
Get the Latest News and Ratings for JANX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors.

Sign Up

JANX Analyst Ratings Over Time

TypeCurrent Forecast
11/15/23 to 11/14/24
1 Month Ago
10/16/23 to 10/15/24
3 Months Ago
8/17/23 to 8/16/24
1 Year Ago
11/15/22 to 11/15/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$66.44$66.13$65.57$28.33
Forecasted Upside28.79% Upside25.38% Upside58.69% Upside222.70% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy

JANX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JANX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Janux Therapeutics Stock vs. The Competition

TypeJanux TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.80
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside27.80% Upside25,262.63% Upside8.06% Upside
News Sentiment Rating
Neutral News

See Recent JANX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$63.00 ➝ $63.00+16.62%
11/7/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00+78.89%
10/24/2024UBS Group
4 of 5 stars
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$69.00+33.33%
9/6/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+60.15%
8/9/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSector Perform ➝ Sector Perform$47.00 ➝ $42.00+17.12%
8/8/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$74.00 ➝ $74.00+108.27%
4/16/2024Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+34.98%
3/21/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$62.00+58.45%
3/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$24.00 ➝ $48.00+22.79%
2/27/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:13 PM ET.


JANX Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Janux Therapeutics is $66.44, with a high forecast of $100.00 and a low forecast of $42.00.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JANX shares.

According to analysts, Janux Therapeutics's stock has a predicted upside of 28.79% based on their 12-month stock forecasts.

Janux Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Stifel Nicolaus, and UBS Group in the past 90 days.

Analysts like Janux Therapeutics more than other "medical" companies. The consensus rating score for Janux Therapeutics is 2.90 while the average consensus rating score for "medical" companies is 2.80. Learn more on how JANX compares to other companies.


This page (NASDAQ:JANX) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners